SHH · 688315.SS
Novogene Co., Ltd.
CN¥19.68+CN¥0.43 (+2.23%)
Novogene Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.01% below the high.
Loading market information…
SHH · 688389.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:11 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Shenzhen Lifotronic Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.09% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Shenzhen Lifotronic Technology Co., Ltd.’s forward annual dividend is CN¥0.28 per share, paid annual. The forward yield is 2.39% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Shenzhen Lifotronic Technology Co., Ltd.’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Shenzhen Lifotronic Technology Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2008 and headquartered in Shenzhen, China, Shenzhen Lifotronic Technology Co., Ltd. specializes in the design, production, and distribution of a wide range of medical devices throughout China, addressing both diagnostic and therapeutic requirements. Its extensive portfolio includes In Vitro Diagnostic (IVD) products, featuring sophisticated analytical instruments such as HPLC systems for hemoglobin and HbA1c measurements, automated ECL immunoassay analyzers, and hematology analyzers. The company also provides Point-of-Care Testing (POCT) solutions, including immunofluorescence analyzers, alongside molecular diagnostics equipment like automated nucleic acid purification systems and real-time PCR platforms. Additionally, Lifotronic offers rapid test kits for key infectious diseases such as COVID-19, malaria, dengue, and influenza A and B. In the therapeutic sector, the company delivers a diverse array of solutions. Respiratory and ICU products encompass video laryngoscopes, warmer units with disposable blankets, high-flow humidification systems, high-frequency chest wall oscillation devices, and intermittent pneumatic compression pumps. For wound care, offerings include negative pressure wound therapy, ultrasound-assisted wound debridement, and wound healing light therapy. Pain management is addressed through ESWT (Extracorporeal Shockwave Therapy) devices, specifically electromagnetic and extracorporeal shockwave systems. Furthermore, Lifotronic is active in medical and aesthetic laser technologies, providing intensive pulsed light systems, fractional CO2 laser systems, Q-switched Nd:YAG laser systems, and fiber laser hair removal systems.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥291.25M |
| Q3 2024 | Oct 28, 2024 | CN¥0.20-9.27% vs estimate | CN¥266.86M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥19.68+CN¥0.43 (+2.23%)
Novogene Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.01% below the high.
CN¥42.25+CN¥2.28 (+5.7%)
Aidite Qinhuangdao Technology Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 55.53% below the high.
CN¥51.86+CN¥0.65 (+1.27%)
Qingdao NovelBeam Technology Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 69.67% below the high.
CN¥7.05+CN¥0.27 (+3.98%)
Jinghua Pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.49% below the high.
CN¥10.06+CN¥0.30 (+3.07%)
Zhejiang Int'l Group Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.94% below the high.
CN¥9.38+CN¥0.14 (+1.52%)
Jiangxi Sanxin Medtec Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 12.99% below the high.
CN¥19.87+CN¥0.07 (+0.35%)
Shenzhen Weiguang Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.02% below the high.
CN¥26.64+CN¥0.38 (+1.45%)
Jianmin Pharmaceutical Group Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.85% below the high.
